NO20074594L - 39-Desmetoksy-derivater av rapamycin - Google Patents

39-Desmetoksy-derivater av rapamycin

Info

Publication number: NO20074594L
Authority: NO; Norway
Prior art keywords: diseases; rapamycin; treatment; desmethoxy; derivatives
Prior art date: 2005-03-11

Application number

NO20074594A

Other languages

English (en)

Norwegian (no)

Inventor

Christoph Hendrik Beckmann

Steven James Moss

Rose Mary Sheridan

Mingqiang Zhang

Barrie Wilkinson

Original Assignee

Biotica Tech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-11

Filing date

2007-09-11

Publication date

2007-10-15

2007-09-11 Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd

2007-10-15 Publication of NO20074594L publication Critical patent/NO20074594L/no

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical class NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010017533 Fungal infection Diseases 0.000 abstract 1
208000031888 Mycoses Diseases 0.000 abstract 1
206010052779 Transplant rejections Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
210000003719 b-lymphocyte Anatomy 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000003176 fibrotic effect Effects 0.000 abstract 1
230000008629 immune suppression Effects 0.000 abstract 1
230000006698 induction Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20074594A 2005-03-11 2007-09-11 39-Desmetoksy-derivater av rapamycin NO20074594L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0504994.5A GB0504994D0 (en)	2005-03-11	2005-03-11	Novel compounds
PCT/GB2006/000853 WO2006095185A1 (en)	2005-03-11	2006-03-10	39-desmethoxy derivatives of rapamycin

Publications (1)

Publication Number	Publication Date
NO20074594L true NO20074594L (no)	2007-10-15

Family

ID=34508873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20074594A NO20074594L (no)	2005-03-11	2007-09-11	39-Desmetoksy-derivater av rapamycin

Country Status (24)

Country	Link
US (2)	US7648996B2 (es)
EP (1)	EP1856129B8 (es)
JP (1)	JP5422788B2 (es)
KR (1)	KR20070113282A (es)
CN (2)	CN101175760B (es)
AU (1)	AU2006221786B2 (es)
BR (1)	BRPI0607441A2 (es)
CA (1)	CA2600640C (es)
CR (1)	CR9434A (es)
DK (1)	DK1856129T3 (es)
ES (1)	ES2527530T3 (es)
GB (1)	GB0504994D0 (es)
HR (1)	HRP20150012T1 (es)
IL (1)	IL185688A0 (es)
MX (1)	MX2007011131A (es)
NI (1)	NI200700230A (es)
NO (1)	NO20074594L (es)
NZ (1)	NZ561607A (es)
PL (1)	PL1856129T3 (es)
PT (1)	PT1856129E (es)
RS (1)	RS53778B1 (es)
RU (1)	RU2391346C2 (es)
WO (1)	WO2006095185A1 (es)
ZA (1)	ZA200708601B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2862538B1 (fr) *	2003-11-21	2006-03-03	Galderma Res & Dev	Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
ES2364495T3 (es)	2005-02-03	2011-09-05	The General Hospital Corporation	Método para tratar cáncer resistente a gefitinib.
EP1896018A2 (en) *	2005-03-11	2008-03-12	Biotica Technology Limited	Medical uses of 39-desmethoxyrapamycin and analogues thereof
CN101836980A (zh) *	2005-03-11	2010-09-22	比奥蒂卡科技有限公司	39-去甲氧基雷帕霉素及其类似物的医药用途
AU2016259316B2 (en) *	2005-11-04	2018-09-06	Wyeth Llc	Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2013204788B2 (en) *	2005-11-04	2016-12-08	Wyeth Llc	Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP2009514870A (ja)	2005-11-04	2009-04-09	ワイス	ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
CA2629714A1 (en)	2005-11-14	2007-05-24	Ariad Gene Therapeutics, Inc.	Administration of an mtor inhibitor to treat patients with cancer
GB0609963D0 (en)	2006-05-19	2006-06-28	Biotica Tech Ltd	Novel compounds
JP2010523566A (ja) *	2007-04-05	2010-07-15	ワイスエルエルシー	ワートマニン−ラパマイシンコンジュゲートおよびその使用
TW200845960A (en) *	2007-04-05	2008-12-01	Wyeth Corp	Wortmannin-rapalog conjugate and uses thereof
US20080287675A1 (en) *	2007-05-18	2008-11-20	Abbott Laboratories	Cascade system
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es)	2008-06-17	2018-12-05	Wyeth Llc	Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh)	2008-08-04	2015-12-16	惠氏有限责任公司	4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2365802B1 (en)	2008-11-11	2017-08-02	The Board of Regents,The University of Texas System	Microcapsules of rapamycin and use for treating cancer
SG174382A1 (en)	2009-04-06	2011-11-28	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
WO2011051960A2 (en) *	2009-09-25	2011-05-05	Cadila Healthcare Limited	Process for the preparation of rapamycin derivatives
CA2777128A1 (en)	2009-10-30	2011-05-05	Ariad Pharmaceuticals, Inc.	Methods and compositions for treating cancer
US20170079962A1 (en)	2009-11-11	2017-03-23	Rapamycin Holdings, Llc	Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
EP2589383A1 (en) *	2011-11-06	2013-05-08	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin	FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en)	2011-12-23	2012-02-01	Biotica Tech Ltd	Novel compound
US20150290176A1 (en)	2012-10-12	2015-10-15	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors to treat vascular cognitive impairment
EP2968281B1 (en)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor inhibitors for prevention of intestinal polyp growth
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
CN105764501A (zh)	2013-07-26	2016-07-13	现代化制药公司	改善比生群治疗效益的组合物
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
AU2014373683B2 (en)	2013-12-31	2020-05-07	Rapamycin Holdings, Llc	Oral rapamycin nanoparticle preparations and use
WO2016040806A1 (en)	2014-09-11	2016-03-17	The Regents Of The University Of California	mTORC1 INHIBITORS
CN106153755B (zh) *	2015-04-24	2020-02-14	山东新时代药业有限公司	2-(叔丁基二甲基硅烷基氧基)乙醇的分析检测方法
US20180258100A1 (en) *	2015-08-28	2018-09-13	Matthew Alan Gregory	RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
JP2020507632A (ja) *	2017-02-10	2020-03-12	マウントタムセラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc.	ラパマイシン類似体
EP3848065B1 (en)	2017-05-15	2023-07-26	C. R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
AR112834A1 (es) *	2017-09-26	2019-12-18	Novartis Ag	Derivados de rapamicina
IL314362A (en)	2018-06-15	2024-09-01	Janssen Pharmaceutica Nv	Rapamycin analogs and their uses
EP3880266B1 (en)	2018-11-14	2025-05-07	Lutonix, Inc.	Medical device with drug-eluting coating on modified device surface
WO2020163594A1 (en)	2019-02-07	2020-08-13	The Regents Of The University Of California	Immunophilin binding agents and uses thereof
WO2020209828A1 (en)	2019-04-08	2020-10-15	Bard Peripheral Vascular, Inc.	Medical device with drug-eluting coating on modified device surface
CN110343639B (zh) *	2019-07-23	2021-04-27	中国医药集团总公司四川抗菌素工业研究所	一株产15(s)-o-乙基雷帕霉素的链霉菌
KR20220128345A (ko)	2019-12-05	2022-09-20	아나쿠리아 테라퓨틱스, 인코포레이티드	라파마이신 유사체 및 이의 용도

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4447233A (en)	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4447224A (en)	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en)	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en)	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
US5221670A (en)	1990-09-19	1993-06-22	American Home Products Corporation	Rapamycin esters
US5138051A (en)	1991-08-07	1992-08-11	American Home Products Corporation	Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en)	1991-05-31	1992-12-10	Pfizer Inc.	Use of rapamycin prodrugs as immunosuppressant agents
US5708002A (en) *	1991-09-05	1998-01-13	Abbott Laboratories	Macrocyclic immunomodulators
JP3140228B2 (ja)	1992-02-17	2001-03-05	ファイザー製薬株式会社	新規な大環状ラクトンおよびその生産菌
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB9315914D0 (en) *	1993-07-31	1993-09-15	Smithkline Beecham Plc	Novel compound
US5373014A (en)	1993-10-08	1994-12-13	American Home Products Corporation	Rapamycin oximes
US5378836A (en)	1993-10-08	1995-01-03	American Home Products Corporation	Rapamycin oximes and hydrazones
US5391730A (en)	1993-10-08	1995-02-21	American Home Products Corporation	Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) *	1993-11-22	1995-01-31	American Home Products Corporation	Gem-distributed esters of rapamycin
US5912253A (en)	1993-12-17	1999-06-15	Novartis Ag	Rapamycin derivatives
US5995457A (en) *	1993-12-22	1999-11-30	Jamail; Randall H.	Method of masking data on digital video disks (DVD)
US5389639A (en) *	1993-12-29	1995-02-14	American Home Products Company	Amino alkanoic esters of rapamycin
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5563145A (en)	1994-12-07	1996-10-08	American Home Products Corporation	Rapamycin 42-oximes and hydroxylamines
EP0833828B1 (en)	1995-06-09	2002-11-20	Novartis AG	Rapamycin derivatives
US5780462A (en)	1995-12-27	1998-07-14	American Home Products Corporation	Water soluble rapamycin esters
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
EP1208847B8 (en)	1996-07-30	2007-02-14	Novartis AG	Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6273913B1 (en) *	1997-04-18	2001-08-14	Cordis Corporation	Modified stent useful for delivery of drugs along stent strut
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
US6485514B1 (en) *	1997-12-12	2002-11-26	Supergen, Inc.	Local delivery of therapeutic agents
AU777997B2 (en)	1999-07-09	2004-11-11	Oregon Health And Science University	Compositions and methods for promoting nerve regeneration
US7078552B2 (en)	2000-04-27	2006-07-18	Arizona Board Of Regents	Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs
US6776796B2 (en)	2000-05-12	2004-08-17	Cordis Corportation	Antiinflammatory drug and delivery device
PL409579A1 (pl) *	2001-02-19	2015-03-02	Novartis Ag	Leczenie raka
JP4547911B2 (ja) *	2002-02-01	2010-09-22	アリアド・ファーマシューティカルズ・インコーポレイテッド	リン含有化合物およびその用途
CA2492153C (en) *	2002-07-16	2012-05-08	Biotica Technology Limited	Production of polyketide fkbp-ligand analogues
US7160867B2 (en)	2003-05-16	2007-01-09	Isotechnika, Inc.	Rapamycin carbohydrate derivatives
GB0417852D0 (en)	2004-08-11	2004-09-15	Biotica Tech Ltd	Production of polyketides and other natural products
EP1896018A2 (en)	2005-03-11	2008-03-12	Biotica Technology Limited	Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504995D0 (en) *	2005-03-11	2005-04-20	Biotica Tech Ltd	Use of a compound

2005
- 2005-03-11 GB GBGB0504994.5A patent/GB0504994D0/en not_active Ceased
2006
- 2006-03-10 DK DK06710063.6T patent/DK1856129T3/en active
- 2006-03-10 PL PL06710063T patent/PL1856129T3/pl unknown
- 2006-03-10 RU RU2007137668/04A patent/RU2391346C2/ru not_active IP Right Cessation
- 2006-03-10 KR KR1020077023040A patent/KR20070113282A/ko not_active Ceased
- 2006-03-10 AU AU2006221786A patent/AU2006221786B2/en not_active Ceased
- 2006-03-10 ES ES06710063.6T patent/ES2527530T3/es not_active Expired - Lifetime
- 2006-03-10 EP EP06710063.6A patent/EP1856129B8/en not_active Expired - Lifetime
- 2006-03-10 CN CN200680016325.2A patent/CN101175760B/zh not_active Expired - Fee Related
- 2006-03-10 NZ NZ561607A patent/NZ561607A/en not_active IP Right Cessation
- 2006-03-10 CN CN201410347137.4A patent/CN104211715A/zh active Pending
- 2006-03-10 ZA ZA200708601A patent/ZA200708601B/xx unknown
- 2006-03-10 CA CA2600640A patent/CA2600640C/en not_active Expired - Fee Related
- 2006-03-10 US US11/908,250 patent/US7648996B2/en not_active Expired - Fee Related
- 2006-03-10 MX MX2007011131A patent/MX2007011131A/es active IP Right Grant
- 2006-03-10 JP JP2008500271A patent/JP5422788B2/ja not_active Expired - Fee Related
- 2006-03-10 BR BRPI0607441-3A patent/BRPI0607441A2/pt not_active IP Right Cessation
- 2006-03-10 HR HRP20150012TT patent/HRP20150012T1/hr unknown
- 2006-03-10 WO PCT/GB2006/000853 patent/WO2006095185A1/en not_active Ceased
- 2006-03-10 RS RS20150009A patent/RS53778B1/sr unknown
- 2006-03-10 PT PT67100636T patent/PT1856129E/pt unknown
2007
- 2007-09-03 IL IL185688A patent/IL185688A0/en unknown
- 2007-09-07 NI NI200700230A patent/NI200700230A/es unknown
- 2007-09-11 NO NO20074594A patent/NO20074594L/no not_active Application Discontinuation
- 2007-10-11 CR CR9434A patent/CR9434A/es not_active Application Discontinuation
2009
- 2009-12-03 US US12/630,251 patent/US8008318B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CR9434A (es)	2008-02-22
PT1856129E (pt)	2015-01-16
ZA200708601B (en)	2009-02-25
US7648996B2 (en)	2010-01-19
CA2600640C (en)	2015-10-27
GB0504994D0 (en)	2005-04-20
RU2391346C2 (ru)	2010-06-10
ES2527530T3 (es)	2015-01-26
JP5422788B2 (ja)	2014-02-19
EP1856129B8 (en)	2015-06-03
NI200700230A (es)	2008-05-13
RU2007137668A (ru)	2009-04-20
BRPI0607441A2 (pt)	2010-04-06
US20080188511A1 (en)	2008-08-07
CN104211715A (zh)	2014-12-17
CA2600640A1 (en)	2006-09-14
EP1856129A1 (en)	2007-11-21
PL1856129T3 (pl)	2015-08-31
DK1856129T3 (en)	2015-01-05
JP2008532991A (ja)	2008-08-21
RS53778B1 (sr)	2015-06-30
HRP20150012T1 (xx)	2015-03-27
KR20070113282A (ko)	2007-11-28
AU2006221786A1 (en)	2006-09-14
US8008318B2 (en)	2011-08-30
US20100081682A1 (en)	2010-04-01
EP1856129B1 (en)	2014-10-15
NZ561607A (en)	2011-01-28
CN101175760A (zh)	2008-05-07
IL185688A0 (en)	2008-01-06
WO2006095185A1 (en)	2006-09-14
AU2006221786B2 (en)	2012-02-16
CN101175760B (zh)	2014-08-13
MX2007011131A (es)	2007-11-13

Legal Events

Date	Code	Title	Description
2012-10-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20074594L (no)	2007-10-15	39-Desmetoksy-derivater av rapamycin
IL278951A (en)	2021-01-31	History of 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-6,2-dione and their use in the treatment of IKZF2-dependent diseases
ATE448232T1 (de)	2009-11-15	Substituierte heterozyklen
EP4480543A3 (en)	2025-02-12	Chiral diaryl macrocycle and use thereof in the treatment of cancer
LTC1830843I2 (lt)	2017-03-10	Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
SI1827441T1 (sl)	2011-09-30	Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
CL2008002852A1 (es)	2009-03-27	Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
WO2016196776A3 (en)	2017-01-05	Inhibitors of bruton's tyrosine kinase
IL180979A (en)	2013-07-31	Isoindulin compounds and their use
ECSP104578A (es)	2010-04-30	Derivados de indolilmaleimida como inhibidores de proteína de cinasa c
HK1203489A1 (en)	2015-10-30	Purinone compounds as kinase inhibitors
WO2015048689A8 (en)	2015-05-07	Inhibitors of bruton's tyrosine kinase
CY1122368T1 (el)	2020-07-31	Παραγωγα 3-οξο-2,3,5,8-τετραϋδρο-[1,2,4]τριαζολο[4,3-α]πυριμιδινης για την αγωγη αναπνευστικων νοσων
EA201000092A1 (ru)	2010-06-30	Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
IL288872B1 (en)	2026-04-01	IMIDAZO[1,5-c]PYRIMIDIN-5-AMINE PERI-CONDENSED DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USES IN CANCER TREATMENT
WO2006058868A3 (de)	2006-08-03	Substituierte pteridine zur behandlung von entzündlichen erkrankungen
FR2933979B1 (fr)	2012-08-24	Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
EA201892518A1 (ru)	2019-04-30	ЗАМЕЩЕННЫЕ 5,6,7,8-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИН-3(2H)-ОН И 2,5,6,7-ТЕТРАГИДРО-3H-ПИРРОЛО[2,1-c][1,2,4]ТРИАЗОЛ-3-ОН И ИХ ПРИМЕНЕНИЕ
EP4003355A4 (en)	2023-07-26	DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
WO2020180712A8 (en)	2020-10-15	Anti-tnfr2 antibodies and uses thereof
CN109983015A (zh)	2019-07-05	6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用
EP4219458A3 (en)	2023-10-18	Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
EP3790866A4 (en)	2022-03-02	DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
EP4003987A4 (en)	2023-07-26	DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
WO2002013866A3 (en)	2003-03-13	Stimulating neutrophil function to treat inflammatory bowel disease